Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide studied in preclinical models of tissue repair. This article summarises the research landscape, including animal and in vitro findings, and notes the absence of approved clinical u

peptides-pro Editorial

What is BPC-157?

BPC-157, also known as body protection compound 157 or Body Protective Compound-157, is a synthetic pentadecapeptide derived from a gastric protein fragment [3][4]. It is classified as a cytoprotective and regenerative peptide, and its reported activities include modulation of angiogenesis, collagen synthesis, fibroblast function, and nitric oxide pathways [4]. The evidence block does not provide its sequence, molecular formula, or molecular weight. Research on this compound centres on its interaction with nitric oxide signalling and its effects on tissue repair processes [4][8].

Despite more than three decades of preclinical investigation, BPC-157 has no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial [3]. The studies summarised below are drawn from animal models, in vitro systems, and one registered human pilot trial that is not yet reported.

Research Studies

BPC-157 and tendon healing in a rat Achilles model

A study in male Sprague-Dawley rats evaluated the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses [9]. This reference-only item reports on the animal model but does not provide outcome details in the evidence block.

BPC-157 and vascular tone in human internal mammary artery

In a study using residual internal mammary artery segments obtained from elective coronary artery bypass graft surgeries (n = 12), researchers investigated the effects of BPC-157 on vascular tone and the contribution of endothelial nitric oxide signalling [8]. The work examined endothelium-dependent, nitric oxide-mediated vasorelaxant effects in human arterial tissue, a setting where functional evidence had previously been limited [8].

BPC-157 and acetylcholinesterase inhibition in vitro

Using a modified Ellman assay and Lineweaver-Burk analysis, investigators examined the inhibitory potential of BPC-157 and two hybrid analogs, CIARA-1 and CIARA-2, against acetylcholinesterase [2]. The hybrid peptides were designed by combining a BPC-157-derived fragment with an arginine-containing C-terminal sequence to enhance interactions with the enzyme's active and peripheral binding sites [2]. All tested compounds showed activity in this in vitro system [2].

BPC-157 and tissue repair mechanisms in preclinical models

A review of preclinical evidence reports that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue [4]. The same review notes reduced inflammatory cytokine activity, improved microvascular integrity, and effects on pain modulation through peripheral and dopaminergic mechanisms in animal models [4]. These findings are derived from preclinical studies, not human trials.

BPC-157 and rotator cuff repair in a human pilot trial

A randomised, double-blind, placebo-controlled pilot trial is investigating BPC-157 in patients undergoing arthroscopic rotator cuff repair (aRCR) [1]. Twenty patients will receive either BPC-157 or saline placebo via daily subcutaneous injections for 90 days following surgery, with all other care following standard postoperative protocols [1]. The trial is registered but results are not yet available; BPC-157 had not previously been studied in formal human clinical trials [1].

BPC-157 and formulation challenges in drug development

A biopharmaceutical review critically evaluates BPC-157 from a drug development perspective, examining its physicochemical and pharmacokinetic properties, formulation challenges across routes of administration, and translational barriers [3]. The review notes that despite consistent biological activity in preclinical research, pharmaceutical development remains rudimentary, with no approved formulation or validated dosing regimen [3].

BPC-157 and chitosan hydrogel fabrication

A study fabricated and characterised a CH/BPC composite hydrogel for physicochemical properties [10]. The formulation exhibited a porous structure as analysed by scanning electron microscopy and transmission electron microscopy [10]. This reference-only item describes a materials science approach to BPC-157 delivery, not a therapeutic evaluation.

BPC-157 and expression in Bacillus licheniformis

Researchers achieved stable expression of γ-glutamyltranspeptidase (GGT)-BPC157 and mScarlet-BPC157 in Bacillus licheniformis strain 2709 by chromosomal integration, optimising fermentation conditions to maximise yield [11]. Under optimal conditions (2% inoculum, 40 g/L soybean peptone, and 80 g/L glucose), the system produced the peptide [11]. This reference-only item concerns production methodology.

BPC-157 and orthobiologics in knee osteoarthritis

A review of orthobiologics in knee osteoarthritis discusses regenerative therapies designed to treat orthopedic conditions, including the use of autologous biological substances [7]. BPC-157 is mentioned within this broader context, but the evidence block does not specify findings for BPC-157 in this indication [7].

BPC-157 and peptide access in sexual medicine

A cross-sectional analysis of all 50 U.S. states and the District of Columbia examined state-level determinants of peptide availability in sexual medicine, using proxy measures to characterise access environments [6]. The study did not focus on BPC-157 specifically but provides a framework for understanding geographic disparities in peptide access [6].

BPC-157 and regenerative medicine for chronic pain

A narrative review summarises evidence on regenerative peptides relevant to chronic pain management, including BPC-157, collagen peptides, thymosin beta-4, thymosin beta-500, and GHK-Cu [12]. This reference-only item provides a broad overview but does not report specific outcomes for BPC-157 in the evidence block [12].

BPC-157 and gastrointestinal cytoprotection

A commentary discusses a lengthy review by Pedrag Sikiric and 21 co-authors in Inflammopharmacology (2024) concerning BPC-157 as a natural pentadecapeptide that acts as a cytoprotectant and is believed to protect the gastrointestinal tract [5]. The evidence block does not provide further details on the findings of that review [5].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp